CoChat

The effect of metformin on blood pressure and metabolism in nondiabetic hypertensive patients

Snorgaard, O., Køber, L., Carlsen, J. · 1997 · Journal of Internal Medicine
Cited by 44

The DOI matches its Crossref record.

Abstract

Snorgaard O, Køber L, Carlsen J (Department of Cardiology and Endocrinology, Frederiksberg Hospital, Department of Cardiology, Gentofte University Hospital, and MEDICON A/S, Copenhagen, Denmark). The effect of metformin on blood pressure and metabolism in nondiabetic hypertensive patients. J Intern Med 1997; 242: 407–412. Objectives: To study the effect of metformin on blood pressure and metabolism in nondiabetic hypertensives. Design: A six‐week single‐blind placebo wash‐out, followed by a double‐blind placebo‐ controlled parallel group design with skew randomization (2:2:1) to metformin 850 mg b.i.d. (n= 10), metformin 500 mg b.i.d. (n= 10), or placebo b.i.d. (n= 5) for 12 weeks. Office blood pressure (oBP), ambulatory blood pressure (aBP), lipoproteins, and oral glucose tolerance (OGTT) were measured/performed before and during treatment. Subjects: Sixteen male and nine female nondiabetic (OGTT) patients (median age 57 (39–74) years) with verified hypertension (White‐coat excluded) for 4 (0–20) years. Results: The possible effect of metformin treatment and dosage was tested with a two‐factor analysis of variance. Treatment induced a significant decline in diastolic oBP, P < 0.05. This decline was, however, not significantly different comparing metformin and placebo. Systolic oBP, diastolic aBP, and systolic aBP showed no significant change by treatment. The decline in diastolic oBP was 5 mmHg in the pooled group of metformin‐ treated patients, P < 0.005. Different gender and the presence of obesity had no impact on the decline in diastolic oBP within this group. Changes in fasting C‐peptide and fasting insulin during treatment were unrelated to blood pressure changes. High fasting insulin (> 60 pmol L−1) or high fasting C‐peptide (> 1000 pmol L−1) at baseline did not favour an effect of metformin on diastolic oBP. Glucose metabolism and lipoproteins were unchanged in all groups. Conclusions: Although metformin treatment induced a decline in diastolic office blood pressure in nondiabetic hypertensives, the decline was not different from that during placebo treatment. Metformin had no significant effect on ambulatory blood pressure. Thus, metformin has, if any, only a minor clinically insignificant effect on blood pressure in nondiabetic hypertensives. The study does not support the hypothesis that circulating insulin is a major regulator of blood pressure in hypertension.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1365-2796.1997.00236.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 44

Metadata

Authors
Snorgaard, O., Køber, L., & Carlsen, J.
Venue
Journal of Internal Medicine
Publisher
Wiley
Published
1997-11
Volume
242
Issue
5
Pages
407-412
ISSN
  • 0954-6820 (ISSN-L)
  • 1365-2796
OpenAlex
W2002815346
Cited by
44
References
0
FWCI
1.86
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The effect of metformin on blood pressure and metabolism in nondiabetic hypertensive patients. https://app.cochat.ai/papers/10.1046/j.1365-2796.1997.00236.x
The paper
Snorgaard, O., Køber, L., & Carlsen, J. (1997). The effect of metformin on blood pressure and metabolism in nondiabetic hypertensive patients. Journal of Internal Medicine. https://doi.org/10.1046/j.1365-2796.1997.00236.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.